These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 14518565)

  • 1. Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol.
    Nakai K; Takenobu Y; Takimizu H; Akimaru S; Maegawa H; Ito H; Marsala M; Katsube N
    Prostaglandins Other Lipid Mediat; 2003 Jul; 71(3-4):253-63. PubMed ID: 14518565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model.
    Nakai K; Takenobu Y; Eguchi K; Takimizu H; Honjo K; Akimaru S; Maegawa H; Marsala M; Katsube N
    Anesth Analg; 2002 Jun; 94(6):1537-41, table of contents. PubMed ID: 12032022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of orally administered OP-1206 alpha-CD with loxoprofen-Na on walking dysfunction in the rat neuropathic intermittent claudication model.
    Nakai K; Takenobu Y; Takimizu H; Akimaru S; Ito H; Maegawa H; Marsala M; Katsube N
    Prostaglandins Leukot Essent Fatty Acids; 2003 Oct; 69(4):269-73. PubMed ID: 12907137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Model of neuropathic intermittent claudication in the rat: methodology and application.
    Takenobu Y; Katsube N; Marsala M; Kondo K
    J Neurosci Methods; 2001 Jan; 104(2):191-8. PubMed ID: 11164245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of extracellular signal-regulated protein kinase in dorsal horn neurons in the rat neuropathic intermittent claudication model.
    Liu Y; Obata K; Yamanaka H; Dai Y; Fukuoka T; Tokunaga A; Noguchi K
    Pain; 2004 May; 109(1-2):64-72. PubMed ID: 15082127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication.
    Hashiguchi M; Ohno K; Saito R
    Yakugaku Zasshi; 2004 Jun; 124(6):321-32. PubMed ID: 15170067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
    Money SR; Herd JA; Isaacsohn JL; Davidson M; Cutler B; Heckman J; Forbes WP
    J Vasc Surg; 1998 Feb; 27(2):267-74; discussion 274-5. PubMed ID: 9510281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model.
    Ishiwata N; Noguchi K; Kawanishi M; Asakura Y; Hori M; Mitani A; Ito Y; Takahashi K; Nishiyama H; Shudo N; Takahashi S; Takahashi K; Tsuruzoe N; Nakaike S
    Life Sci; 2007 Sep; 81(12):970-8. PubMed ID: 17850826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.
    Beebe HG; Dawson DL; Cutler BS; Herd JA; Strandness DE; Bortey EB; Forbes WP
    Arch Intern Med; 1999 Sep; 159(17):2041-50. PubMed ID: 10510990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandin E1 -containing nanoparticles improve walking activity in an experimental rat model of intermittent claudication.
    Ishihara T; Yamashita Y; Takasaki N; Yamamoto S; Hayashi E; Tahara K; Takenaga M; Yamakawa N; Ishihara T; Kasahara T; Mizushima T
    J Pharm Pharmacol; 2013 Aug; 65(8):1187-94. PubMed ID: 23837586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
    Regensteiner JG; Ware JE; McCarthy WJ; Zhang P; Forbes WP; Heckman J; Hiatt WR
    J Am Geriatr Soc; 2002 Dec; 50(12):1939-46. PubMed ID: 12473004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication.
    Dawson DL; Zheng Q; Worthy SA; Charles B; Bradley DV
    Angiology; 2002; 53(5):509-20. PubMed ID: 12365857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of cilostazol and pentoxifylline for treating intermittent claudication.
    Dawson DL; Cutler BS; Hiatt WR; Hobson RW; Martin JD; Bortey EB; Forbes WP; Strandness DE
    Am J Med; 2000 Nov; 109(7):523-30. PubMed ID: 11063952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of withdrawal of drugs treating intermittent claudication.
    Dawson DL; DeMaioribus CA; Hagino RT; Light JT; Bradley DV; Britt KE; Charles BE
    Am J Surg; 1999 Aug; 178(2):141-6. PubMed ID: 10487267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cilostazol: a review of its use in intermittent claudication.
    Chapman TM; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(2):117-38. PubMed ID: 14727939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cilostazol for peripheral arterial disease.
    Robless P; Mikhailidis DP; Stansby GP
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003748. PubMed ID: 17253494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.
    Dawson DL; Cutler BS; Meissner MH; Strandness DE
    Circulation; 1998 Aug; 98(7):678-86. PubMed ID: 9715861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on improvement of blood flow in the chronically compressed cauda equina: comparison between a selective prostaglandin E receptor (EP4) agonist and a prostaglandin E1 derivate.
    Sekiguchi M; Konno S; Kikuchi S
    Spine (Phila Pa 1976); 2006 Apr; 31(8):869-72. PubMed ID: 16622373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cilostazol is effective and safe option for the treatment of intermittent claudication. Results of the NOCLAUD study].
    Farkas K; Járai Z; Kolossváry E
    Orv Hetil; 2017 Jan; 158(4):123-128. PubMed ID: 28116935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cilostazol: new drug. Intermittent claudication: too little efficacy, too many risks.
    Prescrire Int; 2009 Apr; 18(100):56-9. PubMed ID: 19585717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.